Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.33 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.33 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13807765 | 0.91 | FAAH (0.35) | FAAHBAZ2ASHMT1TP53THRB | |
| SCHEMBL4311554 | 0.86 | MAPT (0.34) | SHMT1TP53GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4314876 | 0.77 | RARA (0.37) | FAAHSPRALDH1A1SMN1; SMN2 | |
| SCHEMBL13807752 | 0.76 | SPR (0.35) | FAAHBAZ2ASPRALDH1A1SMN1; SMN2 | |
| SCHEMBL4308899 | 0.76 | CXCR3 (0.48) | — | |
| SCHEMBL13807438 | 0.75 | GPR119 (0.45) | FAAHTHRB | |
| SCHEMBL14495650 | 0.74 | FAAH (0.34) | FAAHBAZ2A | |
| SCHEMBL3596505 | 0.74 | SHMT1 (0.36) | SHMT1TP53GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL14495718 | 0.74 | FAAH (0.40) | FAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL4307217 | 0.72 | MAPT (0.34) | SHMT1TP53GAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | claimed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| EP-1957076-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | FAAH 2880/4885BAZ2A 1912/4885SHMT1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.